What is Juniper Genomics?
Juniper Genomics is at the forefront of IVF innovation, offering the world's first embryo screening test that integrates whole genome and transcriptome sequencing. Established by leading experts in genomics, reproductive medicine, and bioethics, the company provides comprehensive and clinically actionable insights to empower patients and clinicians in making more informed decisions during the IVF process. Unlike conventional methods, Juniper's proprietary approach scrutinizes millions of genetic markers associated with IVF failure, miscarriage, and post-birth health, deliberately avoiding the use of contentious polygenic risk scores. By merging sophisticated scientific advancements with a robust ethical framework, Juniper Genomics is actively shaping the future of reproductive health and establishing a new standard for assessing embryo viability.
How much funding has Juniper Genomics raised?
Juniper Genomics has raised a total of $4.6M across 1 funding round:
Seed
$4.6M
Seed (2025): $4.6M with participation from Innospark Ventures, MBX Capital, Blue Collective, and Amboy Street Ventures
Key Investors in Juniper Genomics
Innospark Ventures
Innospark Ventures is an investment firm that supports founders addressing complex challenges through Artificial Intelligence, focusing on applied AI and deep technology in sectors such as healthcare and life sciences.
MBX Capital
MBX Capital is a boutique venture capital firm that partners with and creates healthcare and biotechnology companies disrupting conventions in service to public health, primarily focusing on early-stage companies.
Blue Collective
Blue Collective is a venture capital and private equity firm that invests in exceptional individuals building remarkable businesses, employing a people-first and values-driven approach.
What's next for Juniper Genomics?
The recent major strategic investment signals a pivotal growth phase for Juniper Genomics, likely enabling the company to scale its operations, expand its research and development initiatives, and broaden its market reach. This infusion of capital is expected to accelerate the adoption of its groundbreaking embryo screening technology, further solidifying its position as a leader in reproductive genomics. Juniper Genomics is poised to continue its trajectory of innovation, aiming to enhance IVF success rates and improve patient outcomes globally.
See full Juniper Genomics company page
